{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:39:32Z","timestamp":1792654772768,"version":"4.5.0"},"reference-count":85,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Osteoporosis is a chronic condition characterized by decreased bone mass, loss of skeletal integrity, and increased susceptibility to fracture. Drugs used to treat osteoporosis can be classified as those that block bone resorption (antiresorptive), stimulate bone formation (anabolic), or do both. While all currently approved medications reduce the risk of fragility fractures in high-risk populations, they are generally unable to fully restore bone strength in most patients with established disease. Thus, the majority of patients require disease management over many years. Unfortunately, the continuous use of a single drug has limitations, both in terms of efficacy and safety, and so sequential therapy is commonly required. Given the expanding list of pharmacological agents currently available, careful consideration needs to be given as to which drugs to use and in what sequence. This review will evaluate the differential effects of antiresorptive, bone-forming, and dual-acting drugs when used in specific sequences and will explore the current evidence favoring the initial use of bone-forming\/dual-acting drugs followed by antiresorptive medications. This review will also examine the notion that long-term treatment with an antiresorptive drug may diminish the efficacy of subsequent treatment with a bone-forming\/dual-acting drug. Finally, this review will explore the current evidence pertaining to the specific issue of how to best prevent the clinical ramifications of denosumab cessation.<\/jats:p>","DOI":"10.1210\/clinem\/dgad496","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:28:13Z","timestamp":1692710893000},"page":"303-311","source":"Crossref","is-referenced-by-count":87,"title":["Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis"],"prefix":"10.1210","volume":"109","author":[{"given":"Sabashini K","family":"Ramchand","sequence":"first","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2051-0505","authenticated-orcid":false,"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Harvard University , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"issue":"1-2","key":"2024011817411116700_dgad496-B1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","article-title":"Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"6","author":"Strom","year":"2011","journal-title":"Arch Osteoporos"},{"issue":"5","key":"2024011817411116700_dgad496-B2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"2024011817411116700_dgad496-B3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ageing\/afu123","article-title":"Admission for osteoporotic pelvic fractures and predictors of length of hospital stay, mortality and loss of independence","volume":"44","author":"Marrinan","year":"2015","journal-title":"Age Ageing"},{"issue":"1","key":"2024011817411116700_dgad496-B4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12891-021-03960-z","article-title":"Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario","volume":"22","author":"Brown","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"2024011817411116700_dgad496-B5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.1997.12.1.24","article-title":"Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation","volume":"12","author":"Ray","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"4983","key":"2024011817411116700_dgad496-B6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/206489a0","article-title":"Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling","volume":"206","author":"Hattner","year":"1965","journal-title":"Nature"},{"key":"2024011817411116700_dgad496-B7","first-page":"315","volume-title":"Osteoporosis.","author":"Parfitt","year":"1996"},{"issue":"1","key":"2024011817411116700_dgad496-B8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02013227","article-title":"Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age","volume":"26","author":"Lips","year":"1978","journal-title":"Calcif Tissue Res"},{"issue":"1","key":"2024011817411116700_dgad496-B9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024011817411116700_dgad496-B10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1056\/NEJMoa1916525","article-title":"Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates","volume":"383","author":"Black","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2024011817411116700_dgad496-B11","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024011817411116700_dgad496-B12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"5","key":"2024011817411116700_dgad496-B13","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024011817411116700_dgad496-B14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"11","key":"2024011817411116700_dgad496-B15","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/jbmr.448","article-title":"Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study","volume":"26","author":"Brown","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"10102","key":"2024011817411116700_dgad496-B16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"2024011817411116700_dgad496-B17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2024011817411116700_dgad496-B18","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024011817411116700_dgad496-B19","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1210\/jc.2004-2212","article-title":"The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis","volume":"91","author":"Michalska","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024011817411116700_dgad496-B20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2024011817411116700_dgad496-B21","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1210\/jc.2016-1160","article-title":"Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study)","volume":"101","author":"Tsai","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024011817411116700_dgad496-B22","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"2024011817411116700_dgad496-B23","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2024011817411116700_dgad496-B24","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024011817411116700_dgad496-B25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024011817411116700_dgad496-B26","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cell.2021.03.010","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"2024011817411116700_dgad496-B27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167790","article-title":"Reduced OPG expression by osteocytes may contribute to rebound resorption after denosumab discontinuation","author":"Fu","year":"2023","journal-title":"J Clin Invest Insight"},{"key":"2024011817411116700_dgad496-B28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fendo.2020.00250","article-title":"Elevated bone hardness under denosumab treatment, with persisting lower osteocyte viability during discontinuation","volume":"11","author":"Jahn-Rickert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9999","key":"2024011817411116700_dgad496-B29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"2024011817411116700_dgad496-B30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00223-017-0288-x","article-title":"Bone loss after denosumab: only partial protection with zoledronate","volume":"101","author":"Reid","year":"2017","journal-title":"Calcif Tissue Int"},{"key":"2024011817411116700_dgad496-B31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2017.03.006","article-title":"Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-follow-up)","volume":"98","author":"Leder","year":"2017","journal-title":"Bone"},{"issue":"10","key":"2024011817411116700_dgad496-B32","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","article-title":"Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures","volume":"28","author":"Lehmann","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024011817411116700_dgad496-B33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00223-018-0404-6","article-title":"Bone loss after romosozumab\/denosumab: effects of bisphosphonates","volume":"103","author":"Horne","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"12","key":"2024011817411116700_dgad496-B34","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/jbmr.3853","article-title":"Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial","volume":"34","author":"Anastasilakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024011817411116700_dgad496-B35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00223-019-00553-w","article-title":"Effect of zoledronate on bone loss after romosozumab\/denosumab: 2-year follow-up","volume":"105","author":"Horne","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2024011817411116700_dgad496-B36","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1210\/clinem\/dgz095","article-title":"Bone mineral density after transitioning from denosumab to alendronate","volume":"105","author":"Kendler","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2024011817411116700_dgad496-B37","doi-asserted-by":"crossref","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","article-title":"The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis","volume":"138","author":"Makras","year":"2020","journal-title":"Bone"},{"issue":"(10):","key":"2024011817411116700_dgad496-B38","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"Solling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024011817411116700_dgad496-B39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/jbmr.3962","article-title":"A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains","volume":"35","author":"Everts-Graber","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2024011817411116700_dgad496-B40","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.bonr.2020.100290","article-title":"Effect of risedronate on bone loss at discontinuation of denosumab","volume":"13","author":"Laroche","year":"2020","journal-title":"Bone Rep"},{"issue":"7","key":"2024011817411116700_dgad496-B41","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/jbmr.4305","article-title":"Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study","volume":"36","author":"Solling","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024011817411116700_dgad496-B42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/jbmr.4259","article-title":"Efficacy of zoledronic acid in maintaining areal and volumetric bone density after combined denosumab and teriparatide administration: DATA-HD study extension","volume":"36","author":"Ramchand","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024011817411116700_dgad496-B43","doi-asserted-by":"crossref","first-page":"e10512","DOI":"10.1002\/jbm4.10512","article-title":"Skeletal responses to romosozumab after 12 months of denosumab","volume":"5","author":"McClung","year":"2021","journal-title":"JBMR Plus"},{"issue":"7","key":"2024011817411116700_dgad496-B44","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00198-022-06388-w","article-title":"Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women","volume":"33","author":"Ha","year":"2022","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024011817411116700_dgad496-B45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","article-title":"Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis","volume":"31","author":"Ebina","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"1","key":"2024011817411116700_dgad496-B46","first-page":"26","article-title":"Comparison of alendronate versus raloxifene after denosumab discontinuation (CARD): A randomized controlled trial","volume":"38","author":"Tsai","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024011817411116700_dgad496-B47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","article-title":"Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis","volume":"103","author":"Popp","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"(1):","key":"2024011817411116700_dgad496-B48","first-page":"264","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"106","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2024011817411116700_dgad496-B49","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","article-title":"Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates","volume":"28","author":"Uebelhart","year":"2017","journal-title":"Osteoporos Int"},{"issue":"18","key":"2024011817411116700_dgad496-B50","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"issue":"(4):","key":"2024011817411116700_dgad496-B51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00223-018-0437-x","article-title":"Effects of teriparatide in patients with osteoporosis in clinical practice: 42-month results during and after discontinuation of treatment from the European extended Forsteo(R) observational study (ExFOS)","volume":"103","author":"Napoli","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"2024011817411116700_dgad496-B52","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024011817411116700_dgad496-B53","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1210\/clinem\/dgaa048","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update","volume":"105","author":"Shoback","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024011817411116700_dgad496-B54","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1359\/jbmr.070413","article-title":"Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis","volume":"22","author":"Chen","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024011817411116700_dgad496-B55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","article-title":"Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats","volume":"99","author":"Bahar","year":"2016","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2024011817411116700_dgad496-B56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","article-title":"Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial","volume":"29","author":"Bilezikian","year":"2018","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024011817411116700_dgad496-B57","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00198-010-1226-1","article-title":"Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis","volume":"22","author":"Macdonald","year":"2011","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024011817411116700_dgad496-B58","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024011817411116700_dgad496-B59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/jbmr.3042","article-title":"Abaloparatide is an anabolic, but does it spare resorption?","volume":"32","author":"Martin","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024011817411116700_dgad496-B60","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"2024011817411116700_dgad496-B61","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"issue":"(8):","key":"2024011817411116700_dgad496-B62","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1210\/jc.2018-00163","article-title":"ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis","volume":"103","author":"Bone","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2024011817411116700_dgad496-B63","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024011817411116700_dgad496-B64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","article-title":"Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos Int"},{"issue":"5","key":"2024011817411116700_dgad496-B65","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024011817411116700_dgad496-B66","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1210\/jc.2008-0353","article-title":"Open-label study to determine how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide I. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate","volume":"93","author":"Miller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024011817411116700_dgad496-B67","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024011817411116700_dgad496-B68","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3384","article-title":"Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial","volume":"33","author":"Geusens","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024011817411116700_dgad496-B69","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024011817411116700_dgad496-B70","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/jbmr.3198","article-title":"Effects of denosumab and teriparatide transitions on bone microarchitecture and estimated strength: the DATA-switch HR-pQCT study","volume":"32","author":"Tsai","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024011817411116700_dgad496-B71","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"2024011817411116700_dgad496-B72","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"18","key":"2024011817411116700_dgad496-B73","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"(8):","key":"2024011817411116700_dgad496-B74","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"16","key":"2024011817411116700_dgad496-B75","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"2024011817411116700_dgad496-B76","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos Int"},{"key":"2024011817411116700_dgad496-B77","doi-asserted-by":"crossref","first-page":"115574","DOI":"10.1016\/j.bone.2020.115574","article-title":"Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"140","author":"Ebina","year":"2020","journal-title":"Bone"},{"issue":"5","key":"2024011817411116700_dgad496-B78","doi-asserted-by":"crossref","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","article-title":"Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis","volume":"88","author":"Ebina","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2024011817411116700_dgad496-B79","doi-asserted-by":"crossref","first-page":"101068","DOI":"10.1016\/j.bonr.2021.101068","article-title":"Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study","volume":"14","author":"Kobayakawa","year":"2021","journal-title":"Bone Rep"},{"issue":"10","key":"2024011817411116700_dgad496-B80","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00198-021-05925-3","article-title":"Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study","volume":"32","author":"Tominaga","year":"2021","journal-title":"Osteoporos Int"},{"issue":"8","key":"2024011817411116700_dgad496-B81","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024011817411116700_dgad496-B82","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","article-title":"A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab","volume":"31","author":"McClung","year":"2020","journal-title":"Osteoporos Int"},{"issue":"6","key":"2024011817411116700_dgad496-B83","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00198-021-06174-0","article-title":"Romosozumab and antiresorptive treatment: the importance of treatment sequence","volume":"33","author":"Cosman","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024011817411116700_dgad496-B84","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.3039","article-title":"Goal-Directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis","volume":"32","author":"Cummings","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024011817411116700_dgad496-B85","doi-asserted-by":"crossref","first-page":"e10629","DOI":"10.1002\/jbm4.10629","article-title":"Bisphosphonate drug holidays: evidence from clinical trials and real-world studies","volume":"6","author":"Wang","year":"2022","journal-title":"JBMR Plus"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad496\/51306819\/dgad496.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/2\/303\/55523926\/dgad496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/2\/303\/55523926\/dgad496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T17:43:13Z","timestamp":1705599793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/2\/303\/7249092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":85,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,8,23]]},"published-print":{"date-parts":[[2024,1,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad496","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,8,23]]}}}